Antares Pharma Inc patents expiration
1. Tlando patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778922 | ANTARES PHARMA INC | Steroidal compositions |
Jan, 2029
(5 years from now) | |
| US11304960 | ANTARES PHARMA INC | Steroidal compositions |
Jan, 2029
(5 years from now) | |
| US8865695 | ANTARES PHARMA INC | Steroidal compositions |
Jan, 2029
(5 years from now) | |
| US10716794 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US11433083 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US11364249 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US9943527 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US10226473 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US11311555 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US9949985 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US11559530 | ANTARES PHARMA INC | Oral testosterone undecanoate therapy |
Nov, 2037
(14 years from now) | |
| US11464735 | ANTARES PHARMA INC | Fixed dose oral testosterone undecanoate compositions and use thereof |
Apr, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 28, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 28 March, 2022
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...
Dosage: CAPSULE;ORAL
TLANDO family patents
2. Xyosted (autoinjector) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9629959 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US9533102 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US10478560 | ANTARES PHARMA INC | Prefilled syringe injector |
Jan, 2026
(2 years from now) | |
| US11446441 | ANTARES PHARMA INC | Prefilled syringe injector |
Jan, 2026
(2 years from now) | |
| US8562564 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US9180259 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US8021335 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Oct, 2026
(3 years from now) | |
| US11497753 | ANTARES PHARMA INC | Hazardous agent injection system |
Mar, 2030
(6 years from now) | |
| US10279131 | ANTARES PHARMA INC | Injection device with cammed RAM assembly |
Jul, 2031
(7 years from now) | |
| US11446440 | ANTARES PHARMA INC | Needle assisted injection device having reduced trigger force |
Aug, 2031
(7 years from now) | |
| US10905827 | ANTARES PHARMA INC | Injection device with cammed ram assembly |
Aug, 2031
(7 years from now) | |
| US10357609 | ANTARES PHARMA INC | Needle assisted jet injection device having reduced trigger force |
Aug, 2031
(7 years from now) | |
| US10821072 | ANTARES PHARMA INC | Needle assisted jet injection administration of testosterone compositions |
Jun, 2033
(9 years from now) | |
| US10881798 | ANTARES PHARMA INC | Needle assisted injection device having reduced trigger force |
Feb, 2034
(10 years from now) | |
| US11160751 | ANTARES PHARMA INC | Hematocrit modulation through needle assisted jet injection of testosterone |
Oct, 2034
(11 years from now) | |
| US10912782 | ANTARES PHARMA INC | Needle assisted injection administration of testosterone compositions |
Feb, 2035
(11 years from now) | |
| US10238662 | ANTARES PHARMA INC | Needle assisted jet injection administration of testosterone compositions |
Feb, 2035
(11 years from now) | |
| US11191908 | ANTARES PHARMA INC | Syringe shock absorber for use in an injection device |
Oct, 2035
(12 years from now) | |
| US9744302 | ANTARES PHARMA INC | Needle assisted jet injection device having reduced trigger force |
Nov, 2035
(12 years from now) | |
| US9950125 | ANTARES PHARMA INC | Needle assisted jet injection administration of testosterone compositions |
Sep, 2036
(12 years from now) | |
| US10646495 | ANTARES PHARMA INC | Testosterone ester triglyceride formulations |
Aug, 2038
(14 years from now) | |
Drugs and Companies using TESTOSTERONE ENANTHATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Method of administering testosterone enanthate subcutaneously
Dosage: SOLUTION;SUBCUTANEOUS
XYOSTED (AUTOINJECTOR) family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic